To immunomodulate this forum with a dose of Yaronl
Post# of 153849
(Total Views: 631)
Posted On: 04/12/2023 1:16:45 PM
To immunomodulate this forum with a dose of Yaronlimab (I'm surprised no one else mentioned that, cracked me up every time Hansen said that) - nothing really negative has occurred and just because you haven't seen a fireworks PR doesn't mean things aren't moving forward-
-They are working on everything in tandem (Hold lift, Keytruda, HIV cure, long-lasting YL I mean LL, NASH protocol, etc.)
-Some of the items for the hold lift are applicable to future trials
-Lien on IP lifted
-Note duration extended another 2 years
-Cash burn cut dramatically
-Re-iterated how deficient Amarex was since 2014 (assuming this is a minimum of $30-40mm, that buys a LOT of time AND flexibility due to my next point)
-Hansen hadn't heard of YL I mean LL years ago and now can't stop thinking about YL I mean LL.
-Sidenote mention of Nader dropping his lawsuit to get legal fees from them (per the 10Q... you're welcome... get it?)
And I disagree that the hold lift and/or Amarex settlement and/or NASH protocol approval wouldn't lead to a sustainable lift to the share price.
The hold lift would be hugely symbolic showing the FDA is ok with CYDY/new mgmt/the drug going forward - that alone should lead to a sustainable lift.
Similar sentiment for NASH protocol approval.
Amarex settlement, if in tens of millions (and if a follow-up lawsuit, if allowed, is then filed), would buy a ton of time/flexibility/debt shoring up/less dilution/etc. which should also definitely lift the price sustainably.
The above can certainly all happen in 2023 (along w/ CEO title + CMO hire).
What me worry? (btw, to Respert's point, I added a parentheses to ohm's list which may eventually become the replacement to The Canon of Medicine, and it unsurprisingly printed out a picture of Alfred E. Neuman drinking a cup of coffee out of a Cytodyn mug)
-They are working on everything in tandem (Hold lift, Keytruda, HIV cure, long-lasting YL I mean LL, NASH protocol, etc.)
-Some of the items for the hold lift are applicable to future trials
-Lien on IP lifted
-Note duration extended another 2 years
-Cash burn cut dramatically
-Re-iterated how deficient Amarex was since 2014 (assuming this is a minimum of $30-40mm, that buys a LOT of time AND flexibility due to my next point)
-Hansen hadn't heard of YL I mean LL years ago and now can't stop thinking about YL I mean LL.
-Sidenote mention of Nader dropping his lawsuit to get legal fees from them (per the 10Q... you're welcome... get it?)
And I disagree that the hold lift and/or Amarex settlement and/or NASH protocol approval wouldn't lead to a sustainable lift to the share price.
The hold lift would be hugely symbolic showing the FDA is ok with CYDY/new mgmt/the drug going forward - that alone should lead to a sustainable lift.
Similar sentiment for NASH protocol approval.
Amarex settlement, if in tens of millions (and if a follow-up lawsuit, if allowed, is then filed), would buy a ton of time/flexibility/debt shoring up/less dilution/etc. which should also definitely lift the price sustainably.
The above can certainly all happen in 2023 (along w/ CEO title + CMO hire).
What me worry? (btw, to Respert's point, I added a parentheses to ohm's list which may eventually become the replacement to The Canon of Medicine, and it unsurprisingly printed out a picture of Alfred E. Neuman drinking a cup of coffee out of a Cytodyn mug)
(16)
(0)